Non-human animals having a humanized signal-regulatory protein gene

Patent metadata

Field	Value
Publication number	US-9901083-B2
Application number	US-201715615298-A
Country	US
Kind code	B2
Filing date	Jun 6, 2017
Priority date	Sep 23, 2013
Publication date	Feb 27, 2018
Grant date	Feb 27, 2018

Abstract

Genetically modified non-human animals and methods and compositions for making and using the same are provided, wherein the genetic modification comprises a humanization of an endogenous signal-regulatory protein gene, in particular a humanization of a SIRPα gene. Genetically modified mice are described, including mice that express a human or humanized SIRPα protein from an endogenous SIRPα locus.

First claim

We claim:

1. An immunodeficient Rag2 null IL2Rγ null mouse whose genome comprises a replacement of exons 2, 3 and 4 of a mouse SIRPα gene at an endogenous mouse SIRPα locus with exons 2, 3 and 4 of a human SIRPα gene to form a humanized SIRPα gene, wherein said humanized SIRPα gene is operably linked to a mouse SIRPα promoter at said endogenous mouse SIRPα locus, and expresses in said mouse a humanized SIRPα protein comprising an extracellular portion of the human SIRPα protein encoded by said human SIRPα gene and an intracellular portion of the mouse SIRPα protein encoded by said mouse SIRPα gene.

2. The mouse of claim 1 , wherein the humanized SIRPα gene comprises exons 1, 5, 6, 7 and 8 of said mouse SIRPα gene.

3. The mouse of claim 1 , wherein the extracellular portion of said human SIRPα protein comprises amino acid residues 28-362 of said human SIRPα protein.

4. The mouse of claim 1 , wherein said human SIRPα protein comprises the amino acid sequence as set forth in SEQ ID NO: 4.

5. The mouse of claim 1 , wherein the mouse is homozygous for said replacement.

6. A method of engrafting human cells into a mouse, comprising the steps of:
(a) providing an immunodeficient Rag2 null IL2Rγ null mouse whose genome comprises a replacement of exons 2, 3 and 4 of a mouse SIRPα gene at an endogenous mouse SIRPα locus with exons 2, 3 and 4 of a human SIRPα gene to form a humanized SIRPα gene, wherein said humanized SIRPα gene is operably linked to a mouse SIRPα promoter at said endogenous mouse SIRPα locus, and expresses in said mouse a humanized SIRPα protein comprising an extracellular portion of the human SIRPα protein encoded by said human SIRPα gene and an intracellular portion of the mouse SIRPα protein encoded by said mouse SIRPα gene; and
(b) transplanting one or more human cells into the mouse.

7. The method of claim 6 , further comprising a step of:
(c) assaying engraftment of the one or more human cells in the mouse.

8. The method of claim 7 , wherein the step of assaying comprises comparing the engraftment of the one or more human cells to the engraftment in one or more mice whose genome does not comprise said replacement.

9. The method of claim 6 , wherein the human cells are hematopoietic stem cells.

10. The method of claim 6 , wherein the human cells are transplanted intravenously, intraperitoneally, or subcutaneously.

11. The method of claim 6 , wherein said humanized SIRPα gene comprises exons 1, 5, 6, 7 and 8 of said mouse SIRPα gene.

12. The method of claim 6 , wherein the extracellular portion of said human SIRPα protein comprises amino acid residues 28-362 of said human SIRPα protein.

13. The method of claim 6 , wherein said human SIRPα protein comprises the amino acid sequence as set forth in SEQ ID NO: 4.

14. The method of claim 6 , wherein the mouse is homozygous for said replacement.

15. A method of assessing the therapeutic efficacy of a drug targeting human cells, comprising:
providing an immunodeficient Rag2 null IL2Rg null mouse whose genome comprises a replacement of exons 2, 3 and 4 of a mouse SIRPα gene at an endogenous mouse SIRPα locus with exons 2, 3 and 4 of a human SIRPα gene to form a humanized SIRPα gene, wherein said humanized SIRPα gene is operably linked to a mouse SIRPα promoter at said endogenous mouse SIRPα locus, and expresses in said mouse a humanized SIRPα protein comprising an extracellular portion of the human SIRPα protein encoded by said human SIRPα gene and an intracellular portion of the mouse SIRPα protein encoded by said mouse SIRPα gene;
transplanting one or more human cells into the mouse;
administering a drug candidate to said mouse; and
monitoring the human cells in the mouse to determine the therapeutic efficacy of the drug candidate.

16. The method of claim 15 , wherein the human cells are cancer cells, and said drug candidate is an anti-cancer drug candidate.

17. The method of claim 15 , wherein said drug candidate is an antibody.

18. The method of claim 15 , wherein said mouse further comprises human immune cells.

19. The method of claim 18 , wherein the transplanted human cells are cancer cells and said drug candidate is a bispecific antibody that binds to an antigen on the human immune cells and an antigen on the transplanted human cancer cells.

20. The method of claim 18 , wherein said humanized SIRPα gene comprises exons 1, 5, 6, 7 and 8 of said mouse SIRPα gene.

Assignees

• Regeneron Pharma

Inventors

• Murphy Andrew J
• Thurston O Gavin
• Varghese Bindu
• Gurer Cagan

Classifications

• A01K2267/0381

  Animal model for diseases of the hematopoietic system · CPC title

• C12N2800/30

  Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT · CPC title

• A01K2217/072

  maintaining or altering function, i.e. knock in · CPC title

• A01K2217/052

  inducing gain of function · CPC title

• A01K2267/01

  Animal expressing industrially exogenous proteins · CPC title